Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Erratum to: Use of signals and systems engineering to improve the safety of warfarin initiation.

Journal of thrombosis and thrombolysis·2016

Same author

Use of signals and systems engineering to improve the safety of warfarin initiation.

Journal of thrombosis and thrombolysis·2016

Same author

Integration of genetic, clinical, and INR data to refine warfarin dosing.

Clinical pharmacology and therapeutics·2010

Same author

Prediction and management of bleeding in cardiac surgery.

Journal of thrombosis and haemostasis : JTH·2009

Same author

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.

Clinical pharmacology and therapeutics·2008

Same author

Pharmacogenetic dose refinement prevents warfarin overdose in a patient who is highly warfarin-sensitive.

Journal of thrombosis and haemostasis : JTH·2007

Search research articles

Related Experiment Video

Updated: May 12, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Novel anticoagulants and laboratory testing.

¹Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA. eby@wustl.edu

International Journal of Laboratory Hematology

|April 18, 2013

Summary

New oral anticoagulants like dabigatran, rivaroxaban, and apixaban impact coagulation tests. Laboratory experts are crucial for accurate testing and interpretation of these direct oral anticoagulants.

Area of Science:

Clinical Chemistry
Hematology
Pharmacology

Background:

Recent introduction of direct oral anticoagulants (DOACs) has altered clinical practice.
DOACs include oral thrombin inhibitors (e.g., dabigatran) and oral factor Xa inhibitors (e.g., rivaroxaban, apixaban).
These agents affect the utilization and interpretation of coagulation laboratory tests.

Purpose of the Study:

To review the impact of DOACs on coagulation screening and diagnostic tests.
To describe methods for measuring anticoagulant activity of DOACs in plasma.
To highlight the evolving role of laboratory testing in managing DOAC therapy.

Main Methods:

Review of current literature on DOACs and coagulation testing.
Description of analytical methods for DOAC plasma level quantification.

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Experiment Videos

Last Updated: May 12, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Discussion of clinical laboratory expert roles in DOAC management.

Main Results:

DOACs significantly influence results of standard coagulation assays.
Specific assays are available for measuring dabigatran, rivaroxaban, and apixaban activity.
Evidence gaps exist regarding laboratory testing for surveillance and adverse event management.

Conclusions:

Coagulation laboratory testing requires adaptation for DOACs.
Accurate interpretation of coagulation tests in patients on DOACs is essential.
Laboratory experts play a vital role in guiding appropriate testing and interpretation for DOAC therapy.